Recently, Squeeze® technology was used ex vivo to demonstrated that different antigens (synthetic long peptides for Cytomegalovirus (CMV) and HPV16+ tumours, neoantigens and M1 influenza mRNA) delivered to human PBMCS resulted in robust antigen-specific CD8+ T-cell responses highlighting the potential to leverage their platform across a wide variety of diseases [210]. Here, CD8A is linked to neoplasm.